# Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

> **NCT00113048** · PHASE1 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 24 (—)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** CAMPATH (alemtuzumab)

## Key facts

- **NCT ID:** NCT00113048
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 24 (—)
- **Last updated:** 2014-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113048, "Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00113048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*